|
|
News Breaks | | | | October 19, 2012 | | 08:20 EDT |  | NVO | Novo Nordisk's Tresiba and Ryzodeg receive positive opinions from CHMP
Novo Nordisk announced that the Committee for Medicinal Products for Human Use, or CHMP, under the European Medicines Agency, or EMA, adopted positive opinions, recommending marketing authorisations, for Tresiba and Ryzodeg for the treatment of diabetes mellitus in adults. Novo Nordisk expects to receive final marketing authorisation from the European Commission within approximately two months. Subject to the Commission‟s approval and completion of pricing and reimbursement discussions, Novo Nordisk expects to launch Tresiba in a number of European markets in the beginning of 2013. Ryzodeg is currently expected to be launched approximately one year after Tresiba, in the respective markets. | |
|
News For NVO From The Last 14 Days Check below for free stories on NVO the last two weeks. |
|
|
| May 23, 2013 | | 11:54 EDT | | NVO | Novo Nordisk reports 8% weight loss in phase 3a trial with liraglutide
 Subscribe for More Information | |
|
|
|
|
|
|
